Huaxi Biotech (688363): Q1 performance improved markedly, medical and aesthetic business continued to grow
Huaxi Biotech (688363): The inflection point in profitability in the first quarter showed leading growth in the medical terminal business
Huaxi Biotech (688363): Q1 surpassed expectations, high medical and aesthetic growth and significant cost reduction
Huaxi Biotech (688363): The adjustments are showing initial results, but the recovery in performance needs to be further confirmed
Huaxi Biotech (688363): Continued adjustment of skincare products, medical and aesthetic performance picked up markedly in Q1
Huaxi Biotech (688363): 24Q1 profit growth exceeded expectations, profit is expected to continue to recover
Huaxi Biology (688363): First seen the dawn in 1Q24 in 24 years or gradually recovered
Huaxi Biotech (688363): Profit picked up in 2024Q1, looking forward to the completion of the company's transformation and revitalization
Huaxi Biotech (688363): 24Q1 performance gradually improved, looking forward to the results of the company's strategic adjustments
Huaxi Biotech (688363) 2023 Annual Report and 2024 Quarterly Report Review: Accelerated growth in the raw materials and medical terminal business is expected to reach an inflection point after adjustments to the skincare business
Huaxi Biotech (688363): Management changes have dragged down 23 years of performance, waiting for an inflection point in business
Huaxi Biotech (688363) Comment: Revenue is expected to drop by about 4% in '23, and management changes are being upgraded and implemented throughout the year
Huaxi Biotech (688363) 23Q3 Quarterly Report Review: Q3 Performance Is Under Short-Term Pressure, Still Waiting for an Inflection Point in Management
Huaxi Biotech (688363): Skincare business strategy adjustments and sales expense ratio optimized
Research Report Nuggets | Caixin Securities: Maintaining Huaxi Biotech's “buy” rating, the logic of rising volume and prices in the medical and aesthetic business sector is still being interpreted
Huaxi Biotech (688363): It is expected that the cosmetics business is under pressure in the short term, raw materials will be steady, and medical aesthetics will maintain relatively rapid growth
Huaxi Biotech (688363): Effective skincare continues to slow, expect organizational changes, results, and performance recovery
Huaxi Biotech (688363): The cosmetics business may continue to put pressure on the medical and aesthetic business or grow further
Huaxi Biotech (688363) 2023 Third Quarter Report Review: Skincare Business Adjustments, Changes, and Medical Aesthetic Business Development Is Booming
Deep* Company* Huaxi Biotech (688363): Q3 revenue declined, skincare business deepened reforms
No Data